The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
"Casgevy offers an effective cure for transfusion-dependent beta thalassaemia for people without a stem cell donor," she added, whilst pointing out there is also a desperate need for new options ...
On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...
Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...
Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.
A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in ...
Oxford Mail on MSN6d
Oxfordshire student to receive new sickle cell treatmentAn Oxfordshire university student is among those set to receive a "transformative" gene-therapy treatment on the NHS for sickle ...
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback